Booming Celltrion Falls After FDA Warning Letter
Celltrion are down more than 5 percent after the company announced it received a warning letter from the FDA after the regulatory agency inspected a company drug manufacturing facility. Source:…
Lilly Exploring Strategic Alternatives for Animal Health Biz
Sluggish growth is the main driver for the decision.. Source: BioSpace
Investors Elated as Vertex Picks Two Top CF Triple Combos for Phase III Trials
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy. Source: BioSpace
Cambridge's AVROBIO Lands $60M to Push Fabry, Rest of Pipeline Into the Clinic
The company plans to initiate a Phase 2 clinical trial this year with AVR-RD-01 in Fabry disease. Source: BioSpace
Stada Names Novartis Exec as New CEO, It's Fifth Leader Since 2016
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board. Source: BioSpace
Voyager Founder and CEO to Step Down, Hunt for New Leader Begins
Dr. Paul has been with the company for six years since its inception, initially as president of R&D, Source: BioSpace
3 Big Drugmakers With Huge Catalysts on the Horizon
A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect. Source: BioSpace
On a Roll: Sage Shows Off Early-Stage Insomnia Data
The new data supports further development of SAGE-217 in disorders associated with disruption of normal sleep. Source: BioSpace
Meet the Unnoticed Alzheimer's Biotech Facing a Make-or-Break 2018
It seems that the primary news surrounding Alzheimer's disease research has been nothing but negative for years. Source: BioSpace
Get Ready for the M&A Explosion
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers. Source: BioSpace
- Go to the previous page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- …
- 288
- Go to the next page